...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma
【24h】

External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma

机译:食管癌外照射联合腔内近距离放射治疗

获取原文
获取原文并翻译 | 示例

摘要

Purpose: To assess the effectiveness of definitive radiation therapy in patients with potentially curable esophageal cancer and to evaluate the side-effects of this treatment. Methods and materials: Sixty-two patients with esophageal cancer, who were treated with definitive, curatively intended radiotherapy consisting of external radiotherapy (60 Gy in 30 fractions), preceded and followed by LDR or HDR intraluminal brachy (12 Gy in 2 fractions) were retrospectively analyzed. Results: Recurrences were reported in 38 patients (61%), of which 25 (64%) failed locally first. The overall survival rates at 1, 2 and 5 years were 57%, 34% and 11%, respectively. The median overall survival was 15 months. No prognostic factors could be identified. Most frequently reported treatment related toxicities were esophagitis, ulcerations, (11%) and strictures (16%). In 10 patients (16%) severe toxicities, were reported including grade III ulceration (2 cases), stricture (1 case), radiation pneumonitis (1 case), perforation (1 case), esophageal-pleural-tracheal fistula (1 case), and acute esophageal bleeding (4 cases). A history of gastrectomy was significantly associated with the development of severe toxicity. Conclusion: Curatively intended radiotherapy alone can be offered to esophageal cancer patients, even when surgery and/or chemotherapy are not feasible. However, we observed severe toxicity in a substantial part of the patients. Given the relatively high rate of severe complications and the uncertainties regarding dose escalation, the addition of brachytherapy, with consequently high surface doses, should be limited to well-selected patients.
机译:目的:评估确定性放射治疗对可能治愈的食道癌患者的有效性,并评估这种治疗的副作用。方法和材料:62例食管癌患者接受了明确的,有针对性的放疗,包括外放疗(60 Gy分30份),然后进行LDR或HDR腔内近距离放散(2分12 Gy)。进行回顾性分析。结果:据报道有38例患者(61%)复发,其中25例(64%)首先在局部失败。在1、2和5年的总生存率分别为57%,34%和11%。中位总生存期为15个月。无法确定预后因素。最常报告的与治疗有关的毒性是食道炎,溃疡(11%)和狭窄(16%)。据报告有10例严重毒性反应(16%),包括三级溃疡(2例),狭窄(1例),放射性肺炎(1例),穿孔(1例),食管-胸膜-气管瘘(1例) ,以及急性食道出血(4例)。胃切除术史与严重毒性反应显着相关。结论:即使在手术和/或化学疗法不可行的情况下,食管癌患者也可以单独接受治疗性放疗。但是,我们在相当一部分患者中观察到了严重的毒性反应。鉴于严重并发症的发生率相对较高,以及剂量递增的不确定性,因此应仅对经过精心挑选的患者进行近距离放射治疗,以及随之而来的高表面剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号